BIO FY 2020 Earnings Report — Bio-Rad Laboratories, Inc. Revenue & Financial Results | Market Cap Arena

Bio-Rad Laboratories, Inc.BIO

FY 2020 Earnings

Reported February 12, 2021

Quarter Comparison

Revenue

Operating Income

Gross Margin

Net Margin

EPS (Diluted)

Free Cash Flow

Metric	FY 2020	Prior Q	FY 2019	QoQ Change	YoY Change
Revenue	$2.5B	—	$2.3B	—	10.1%
Op. Income	$421M	—	$230M	—	83.5%
Gross Margin	56.5%	—	54.4%	—	2.1pp
Net Margin	149.8%	—	76.1%	—	73.8pp
EPS (Diluted)	$126.20	—	$58.27	—	116.6%
Free Cash Flow	$476M	—	$359M	—	32.6%

Revenue Flow

Item	Amount
REVENUE	$2.5B
Cost of Revenue	$1.1B
GROSS PROFIT	$1.4B
R&D Expenses	$218M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$799M
Other Expenses	$0
Operating Expenses	$1.0B
Cost & Expenses	$2.1B
OPERATING INCOME	$421M
Interest Income	$18M
Interest Expense	$22M
Other Income/Expenses	$4.5B
INCOME BEFORE TAX	$4.9B
Income Tax Expense	$1.1B
Net Income from Continuing Ops	$3.8B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$3.8B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$3.8B
D&A	$139M
EBIT	$4.9B
EBITDA	$5.1B
EPS	$128
EPS Diluted	$126

Income Statement

Item	Amount
REVENUE	$2.5B
Cost of Revenue	$1.1B
GROSS PROFIT	$1.4B
R&D Expenses	$218M
Selling & Marketing	$0
General & Administrative	$0
SG&A Expenses	$799M
Other Expenses	$0
Operating Expenses	$1.0B
Cost & Expenses	$2.1B
OPERATING INCOME	$421M
Interest Income	$18M
Interest Expense	$22M
Other Income/Expenses	$4.5B
INCOME BEFORE TAX	$4.9B
Income Tax Expense	$1.1B
Net Income from Continuing Ops	$3.8B
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	$3.8B
Net Income Deductions	$0
BOTTOM LINE NET INCOME	$3.8B
D&A	$139M
EBIT	$4.9B
EBITDA	$5.1B
EPS	$128
EPS Diluted	$126

Cash Flow Statement

Item	Amount
Net Income	$3.8B
Depreciation & Amortization	$139M
Stock-Based Compensation	$42M
Deferred Income Tax	$0
Other Non-Cash Items	-$4.5B
Change in Working Capital	$1.1B
OPERATING CASH FLOW	$585M
Capital Expenditure	-$109M
Acquisitions (Net)	-$84M
Purchases of Investments	-$248M
Sales/Maturities of Investments	$368M
Other Investing Activities	$3M
NET CASH FROM INVESTING	-$70M
Net Debt Issuance	-$427M
Common Stock Repurchased	-$100M
Common Dividends Paid	$0
Other Financing Activities	$4M
NET CASH FROM FINANCING	-$523M
FREE CASH FLOW	$476M
Net Change in Cash	$4M

Balance Sheet

Item	Amount
Cash & Equivalents	$662M
Short-Term Investments	$329M
Net Receivables	$419M
Inventory	$622M
Other Current Assets	$16M
TOTAL CURRENT ASSETS	$2.1B
PP&E (Net)	$694M
Goodwill	$292M
Intangible Assets	$200M
Long-Term Investments	$9.6B
Tax Assets	$0
Other Non-Current Assets	$87M
TOTAL NON-CURRENT ASSETS	$10.8B
TOTAL ASSETS	$13.0B
Account Payables	$139M
Short-Term Debt	$1M
Deferred Revenue	$42M
Other Current Liabilities	$131M
TOTAL CURRENT LIABILITIES	$632M
Long-Term Debt	$1M
Deferred Revenue NC	$0
Deferred Tax Liabilities	$2.1B
Other Non-Current Liabilities	$197M
TOTAL NON-CURRENT LIABILITIES	$2.5B
TOTAL LIABILITIES	$3.1B
Common Stock	$3.0K
Additional Paid-In Capital	$429M
Retained Earnings	$9.3B
Treasury Stock	-$100M
Accum. Other Comp. Income	$282M
Other Equity	$0
TOTAL STOCKHOLDERS' EQUITY	$9.9B
Minority Interest	$0
TOTAL EQUITY	$9.9B
TOTAL LIABILITIES & EQUITY	$13.0B
Total Debt	$226M
Net Debt	-$436M